Topical Application of Imiquimod as a Treatment for Chromoblastomycosis

Chromoblastomycosis is a subcutaneous mycosis that remains a therapeutic challenge, with no standard treatment and high rates of relapse. On the basis of our recent discoveries in mouse models, we tested the efficacy of topical applications of imiquimod to treat patients afflicted with this chronic fungal infection. We report results of treatment for the first 4 recipients of topical imiquimod, all of whom displayed a marked improvement of their lesions, both with and without concurrent oral antifungal therapy.

• Publication year

  2014

• Venue

  Clinical Infectious Diseases

• Publication date

  2014-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/cid/ciu168PMID 24633683PMCID 4036686
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Restoration of Pattern Recognition Receptor Costimulation to Treat Chromoblastomycosis, a Chronic Fungal Infection of the Skin

  2011cited by this paper
• Chromoblastomycosis: study of 27 cases and review of medical literature.

  2010cited by this paper
• Cromoblastomicose: relato de 27 casos e revisão da literatura

  2010cited by this paper
• Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment.

  2009cited by this paper
• Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis1

  2009cited by this paper
• Fonsecaea pedrosoi infection induces differential modulation of costimulatory molecules and cytokines in monocytes from patients with severe and mild forms of chromoblastomycosis

  2008cited by this paper
• Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial.

  2006cited by this paper
• Phagocytosis, production of nitric oxide and pro-inflammatory cytokines by macrophages in the presence of dematiaceous [correction of dematiaceus] fungi that cause chromoblastomycosis.

  2006cited by this paper
• Phagocytosis, Production of Nitric Oxide and Pro‐inflammatory Cytokines by Macrophages in the Presence of Dematiaceus Fungi that Causes Chromoblastomycosis

  2006cited by this paper
• Successful treatment of antifungal- and cryotherapy-resistant subcutaneous hyalohyphomycosis in an immunocompetent case with topical 5% imiquimod cream

  2005cited by this paper
• Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.

  2005cited by this paper
• Cytokines and lymphocyte proliferation in patients with different clinical forms of chromoblastomycosis.

  2005cited by this paper
• Imiquimod.

  2003cited by this paper
• Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action.

  1999cited by this paper

• Dermatological Fungal Neglected Tropical Diseases

  2025cites this paper
• Approach to Diagnosing and Managing Implantation Mycoses.

  2025cites this paper
• Chromoblastomycosis in Peru: a retrospective review of 13 cases

  2025cites this paper
• Chromoblastomycosis in Northern Taiwan from 2017 to 2024: Unique Characteristics.

  2025cites this paper
• Research Progress on Host Genetic Susceptibility and Immune Microenvironment Regulation Mechanisms in Chromoblastomycosis

  2025cites this paper
• The Current Landscape of Repurposed Drugs for Fungal Neglected Tropical Diseases

  2025cites this paper
• Dermatologic Fungal Neglected Tropical Diseases-Part II. Management and Morbidity.

  2024cites this paper
• Chromoblastomycosis in Brazil: A review of 450 published cases

  2024cites this paper
• The pathobiology of human fungal infections

  2024cites this paper
• Successful management of chromoblastomycosis utilizing conventional antifungal agents and imiquimod therapy

  2024cites this paper
• Chromoblastomycosis in French Guiana: Epidemiology and Practices, 1955–2023

  2024cites this paper
• A Community-Acquired Tropical Skin Disease.

  2023cites this paper
• Chromoblastomycosis: New Perspective on Adjuvant Treatment with Acitretin

  2023cites this paper
• Chromoblastomycosis: A Case Series and Literature Review

  2023cites this paper
• Immunotherapies inducing immunogenic cell death in cancer: insight of the innate immune system

  2023cites this paper
• Host defense mechanisms against Candida auris

  2023cites this paper
• Rare Presentation of Chromoblastomycosis Due to Multiple Simultaneous Inoculations: A Case Report

  2023cites this paper
• Exploiting antifungal immunity in the clinical context.

  2023cites this paper
• Chromoblastomycosis Treated With Posaconazole and Adjunctive Imiquimod: Lending Innate Immunity a Helping Hand

  2023cites this paper
• The origin of human pathogenicity and biological interactions in Chaetothyriales

  2023cites this paper
• Immune responses to human fungal pathogens and therapeutic prospects

  2023cites this paper
• Tackling the emerging threat of antifungal resistance to human health

  2022cites this paper
• C‐type lectin receptors in antifungal immunity: Current knowledge and future developments

  2022cites this paper
• Chromomycosis

  2022cites this paper
• A Community-Acquired Tropical Skin Disease.

  2022cites this paper
• Molecular Characteristics of Regional Chromoblastomycosis in Guangdong, China: Epidemiological, Clinical, Antifungal Susceptibility, and Serum Cytokine Profiles of 45 Cases

  2022cites this paper
• The global burden of chromoblastomycosis

  2021cites this paper
• Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis

  2021cites this paper
• Neutrophil-suppressive activity over T-cell proliferation and fungal clearance in a murine model of Fonsecaea pedrosoi infection

  2021cites this paper
• Case Report: Short-Term Application of Topical Imiquimod Is Practical for Chromoblastomycosis.

  2021cites this paper
• Managing chromoblastomycosis with acitretin plus imiquimod: A case report on the improvement of cutaneous lesions and reduction of the treatment time

  2021cites this paper
• Host cell membrane microdomains and fungal infection

  2021cites this paper
• The potential role for topical imiquimod in the treatment of chronic mucocutaneous candidiasis caused by gain‐of‐function mutation in STAT1: A case‐report

  2021cites this paper
• Effect of Fonsecaea monophora on the Polarization of THP-1 Cells to Macrophages

  2020cites this paper
• Successful treatment of chromoblastomycosis caused by Fonsecaea pedrosoi using imiquimod

  2020cites this paper
• Plasma membrane receptors of tissue macrophages: functions and role in pathology

  2020cites this paper
• Effect of Imiquimod on Tachyzoites of Toxoplasma gondii and Infected Macrophages in vitro and in BALB/c Mice

  2020cites this paper
• Case Report: Treatment of Chromoblastomycosis with Combinations including Acitretin: A Report of Two Cases.

  2020cites this paper
• Chromoblastomycosis in an Endemic Area of Brazil: A Clinical-Epidemiological Analysis and a Worldwide Haplotype Network

  2020cites this paper
• Intracellular PRRs Activation in Targeting the Immune Response Against Fungal Infections

  2020cites this paper
• From bench to bedside - translational approaches in anti-fungal immunology.

  2020cites this paper
• Skin Fungal Infections in Children: Diagnostic Challenges

  2020cites this paper
• Immune Sensing and Potential Immunotherapeutic Approaches to Control Chromoblastomycosis

  2020cites this paper
• Pattern recognition receptors in fungal immunity

  2019cites this paper
• Host Defenses to Fungal Pathogens

  2019cites this paper
• Fungal immunology in clinical practice: Magical realism or practical reality?

  2019cites this paper
• Trichophyton rubrum Elicits Phagocytic and Pro-inflammatory Responses in Human Monocytes Through Toll-Like Receptor 2

  2019cites this paper
• Successful treatment of chromoblastomycosis of 10‐year duration due to Fonsecaea nubica

  2018cites this paper
• Pneumocystis and interactions with host immune receptors

  2018cites this paper
• Continuing medical education

  2018cites this paper
• Host Control of Fungal Infections: Lessons from Basic Studies and Human Cohorts.

  2018cites this paper
• Regulation of C-Type Lectin Receptor-Mediated Antifungal Immunity

  2018cites this paper
• Organ-specific mechanisms linking innate and adaptive antifungal immunity.

  2018cites this paper
• Chromoblastomycosis: clinical experience and review of literature

  2018cites this paper
• Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update

  2018cites this paper
• Immunomodulation as Therapy for Fungal Infection: Are We Closer?

  2018cites this paper
• [Chromomycosis acquired in a non-tropical area: A case report].

  2017cites this paper
• Immunity to Fungal Infections

  2017cites this paper
• Fungal infections 4 Neglected endemic mycoses

  2017cites this paper
• Une chromomycose contractée en zone non tropicale.

  2017cites this paper
• Immunity against fungi.

  2017cites this paper
• Immunotherapy of Invasive Fungal Disease

  2017cites this paper
• Fungal Recognition and Host Defense Mechanisms

  2017cites this paper
• Fungal Vaccines and Immunotherapeutics: Current Concepts and Future Challenges

  2017cites this paper
• Neglected endemic mycoses.

  2017cites this paper
• Immunotherapeutic approaches to treatment of fungal diseases.

  2017cites this paper
• Fungal infections 6 Immunotherapeutic approaches to treatment of fungal diseases

  2017cites this paper
• Chromoblastomycosis and sporotrichosis, two endemic but neglected fungal infections in Madagascar.

  2017cites this paper
• Regulation of Interleukin-23 Expression in Health and Disease.

  2016cites this paper
• Chromoblastomycosis

  2016cites this paper
• Medical mycology and fungal immunology: new research perspectives addressing a major world health challenge

  2016cites this paper
• In situ photoimmunotherapy for cutaneous granuloma caused by itraconazole‐resistant Candida guilliermondii

  2016cites this paper
• Can repurposing of existing drugs provide more effective therapies for invasive fungal infections?

  2016cites this paper
• Advancements in the Management of Chromoblastomycosis Among Immunocompromised Patients: an overview of a case

  2016cites this paper
• Fungal skin and soft tissue infections

  2016cites this paper
• Fonsecaea pedrosoi as a rare cause of acute conjunctival ulceration.

  2016cites this paper
• Tackling emerging fungal threats to animal health, food security and ecosystem resilience

  2016cites this paper
• Immune response in human chromoblastomycosis and eumycetoma – focusing on human interleukin‐17A, interferon‐gamma, tumour necrosis factor‐alpha, interleukin‐1 beta and human beta‐defensin‐2

  2016cites this paper
• UNIVERSIDADE FEDERAL DO MARANHÃO CENTRO DE CIÊNCIAS BIOLÓGICAS E DA SAÚDE PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE

  2015cites this paper
• Fonsecaea pedrosoi‐induced Th17‐cell differentiation in mice is fostered by Dectin‐2 and suppressed by Mincle recognition

  2015cites this paper
• International Union of Basic and Clinical Pharmacology. XCVI. Pattern Recognition Receptors in Health and Disease

  2015cites this paper
• The evolution of our understanding of macrophages and translation of findings toward the clinic

  2015cites this paper
• Immune Interactions with Pathogenic and Commensal Fungi: A Two-Way Street.

  2015cites this paper
• Fungal Infections of Implantation (Chromoblastomycosis, Mycetoma, Entomophthoramycosis, and Lacaziosis)

  2015cites this paper
• Therapeutic and Prophylactic Tools for Sporotrichosis: Current Strategies and Future Tendencies

  2015cites this paper
• Pattern recognition receptors in antifungal immunity

  2014cites this paper